Analysts Offer Insights on Healthcare Companies: Albireo Pharma Inc (NASDAQ: ALBO) and Boston Scientific Corp (NYSE: BSX)

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Albireo Pharma Inc (NASDAQ: ALBO) and Boston Scientific Corp (NYSE: BSX) with bullish sentiments.

Albireo Pharma Inc (NASDAQ: ALBO)

In a report released today, Alan Carr from Needham assigned a Buy rating to Albireo Pharma Inc (NASDAQ: ALBO), with a price target of $35. The company’s shares opened today at $26.10.

Carr said:

“Albireo hosted a KOL meeting yesterday in NYC to discuss Progressive Familial Intrahepatic Cholestasis (PFIC) and provide an update on A4250 clinical program. E. Sturm, investigator in A4250 Phase 2 trial in pediatric cholestasis, highlighted unmet need in PFIC and other rare pediatric cholestasis indications. Biliary diversion surgery is effective option for reducing bile acids in serum, but has 20-40% failure rate. Dr. Sturm is eager for other options and views AB4250 Phase 2 safety and efficacy profile as compelling. Initiation of Phase 3 trial in PFIC1 and PFIC2 patients expected around YE17.”

According to TipRanks.com, Carr is a 4-star analyst with an average return of 7.1% and a 44.2% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.

Currently, the analyst consensus on Albireo Pharma Inc is Strong Buy and the average price target is $46.50, representing a 78.2% upside.

In a report issued on October 24, Wedbush also reiterated a Buy rating on the stock with a $58 price target.
Boston Scientific Corp (NYSE: BSX)

In a report released today, Michael Matson from Needham reiterated a Buy rating on Boston Scientific Corp (NYSE: BSX), with a price target of $32. The company’s shares opened today at $28.82, close to its 52-week high of $29.93.

Matson commented:

“BSX beat consensus 3Q17 revenue and met consensus EPS. Management raised its 2017 revenue guidance and narrowed EPS guidance. BSX’s organic revenue growth slowed to 4% in 3Q17 (with a 10-20 bps negative impact from the hurricanes) from 6% in 2Q17 given a difficult comp and the Lotus recall. The US Lotus launch is still expected in mid-2018, but the European re-launch has been delayed to 1Q18 from 2H17. Margins were mixed with BSX’s gross margin down 30 bps Y/Y and operating margin up 80 bps Y/Y as a larger than expected currency headwind and Hurricane Maria costs were offset by cost reductions, favorable product mix, and SG&A leverage.”

According to TipRanks.com, Matson is a 5-star analyst with an average return of 9.7% and a 60.2% success rate. Matson covers the Healthcare sector, focusing on stocks such as Cardiovascular Systems, Zimmer Biomet Holdings, and Baxter International.

Currently, the analyst consensus on Boston Scientific Corp is Strong Buy and the average price target is $31.89, representing a 10.7% upside.

In a report issued on October 11, BMO Capital also reiterated a Buy rating on the stock with a $30 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.